JP2012506235A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012506235A5 JP2012506235A5 JP2011517539A JP2011517539A JP2012506235A5 JP 2012506235 A5 JP2012506235 A5 JP 2012506235A5 JP 2011517539 A JP2011517539 A JP 2011517539A JP 2011517539 A JP2011517539 A JP 2011517539A JP 2012506235 A5 JP2012506235 A5 JP 2012506235A5
- Authority
- JP
- Japan
- Prior art keywords
- oligopeptide
- antigen
- cancer
- isolated
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000015636 Oligopeptides Human genes 0.000 claims description 52
- 108010038807 Oligopeptides Proteins 0.000 claims description 52
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 24
- 102000040430 polynucleotide Human genes 0.000 claims description 14
- 108091033319 polynucleotide Proteins 0.000 claims description 14
- 239000002157 polynucleotide Substances 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 10
- 230000001939 inductive effect Effects 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 150000001413 amino acids Chemical group 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 210000001808 exosome Anatomy 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 4
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 108091008874 T cell receptors Proteins 0.000 claims description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 230000028993 immune response Effects 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims 6
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19710608P | 2008-10-22 | 2008-10-22 | |
| US61/197,106 | 2008-10-22 | ||
| PCT/JP2009/005382 WO2010047062A1 (en) | 2008-10-22 | 2009-10-15 | Rab6kifl/kif20a epitope peptide and vaccines containing the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012506235A JP2012506235A (ja) | 2012-03-15 |
| JP2012506235A5 true JP2012506235A5 (enExample) | 2012-11-29 |
| JP5663790B2 JP5663790B2 (ja) | 2015-02-04 |
Family
ID=42119117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011517539A Active JP5663790B2 (ja) | 2008-10-22 | 2009-10-15 | Ｒａｂ６ｋｉｆｌ／ｋｉｆ２０ａエピトープペプチドおよびそれを含むワクチン |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US8883966B2 (enExample) |
| EP (1) | EP2362906B1 (enExample) |
| JP (1) | JP5663790B2 (enExample) |
| KR (1) | KR101705150B1 (enExample) |
| CN (2) | CN102264897B (enExample) |
| AR (1) | AR073967A1 (enExample) |
| AU (1) | AU2009305847B2 (enExample) |
| BR (1) | BRPI0919766B1 (enExample) |
| CA (1) | CA2741399C (enExample) |
| CO (1) | CO6362049A2 (enExample) |
| ES (1) | ES2541325T3 (enExample) |
| IL (1) | IL212046A (enExample) |
| MX (1) | MX2011004176A (enExample) |
| NZ (1) | NZ592461A (enExample) |
| RU (1) | RU2532105C2 (enExample) |
| SG (1) | SG195571A1 (enExample) |
| TW (1) | TWI455720B (enExample) |
| UA (1) | UA102274C2 (enExample) |
| WO (1) | WO2010047062A1 (enExample) |
| ZA (1) | ZA201103667B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150359864A1 (en) | 2012-03-09 | 2015-12-17 | Oncotherapy Science, Inc. | Pharmaceutical composition containing peptides |
| US9561265B2 (en) * | 2012-07-10 | 2017-02-07 | Oncotherapy Science, Inc. | KIF20A epitope peptides for TH1 cells and vaccines containing the same |
| MX2019008878A (es) | 2017-01-25 | 2020-02-13 | Ose Immunotherapeutics | Metodo para fabricar una emulsion estable para suministro de peptidos. |
| US10412682B2 (en) * | 2017-08-30 | 2019-09-10 | Qualcomm Incorporated | Mechanism to update/download profile using low power or no power |
| CN107460250B (zh) * | 2017-09-28 | 2020-07-28 | 郑州大学第一附属医院 | 基于kif14、kif15和kif20a基因的透明细胞肾癌诊断试剂盒及其使用方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2084180A1 (en) | 1991-12-11 | 1993-06-12 | Paul P. Hung | Expression of specific immunogens using viral antigens |
| US6783961B1 (en) | 1999-02-26 | 2004-08-31 | Genset S.A. | Expressed sequence tags and encoded human proteins |
| AU765733B2 (en) | 1998-07-28 | 2003-09-25 | Kyogo Itoh | HLA-A2 restraint tumor antigen peptide originating in SART-1 |
| HUP0500345A2 (hu) | 2000-03-29 | 2005-07-28 | Corixa Corporation | Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására |
| CN1469926A (zh) | 2000-03-29 | 2004-01-21 | 科里克萨有限公司 | 治疗和诊断肺癌的组合物和方法 |
| CN100400099C (zh) | 2001-01-04 | 2008-07-09 | 北京迪威华宇生物技术有限公司 | 预防和治疗人前列腺癌的重组蛋白疫苗 |
| JP2005527180A (ja) | 2001-04-18 | 2005-09-15 | プロテイン デザイン ラブス， インコーポレイテッド | 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法 |
| WO2002102235A2 (en) | 2001-06-18 | 2002-12-27 | Eos Biotechnology Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| US20030194704A1 (en) | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
| DK2261249T3 (en) | 2002-09-12 | 2015-02-16 | Oncotherapy Science Inc | KDR peptides and vaccines comprising the same |
| EP1572118A4 (en) | 2002-12-20 | 2010-07-14 | Millennium Pharm Inc | METHOD AND COMPOSITIONS FOR TREATING CANCER WITH 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 216 |
| WO2005019258A2 (en) | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| US8143228B2 (en) | 2004-07-12 | 2012-03-27 | Medical Research Fund Of Tel Aviv Sourasky Medical Center | Agents capable of downregulating an MSF-A dependent HIF-1α and use thereof in cancer treatment |
| CN100381460C (zh) | 2004-11-30 | 2008-04-16 | 北京市肿瘤防治研究所 | Her-2模拟抗原表位及含有该表位的肽 |
| JP5109131B2 (ja) | 2005-02-10 | 2012-12-26 | オンコセラピー・サイエンス株式会社 | 膀胱癌を診断する方法 |
| PL2325306T3 (pl) | 2005-02-25 | 2014-07-31 | Oncotherapy Science Inc | Szczepionki peptydowe do zastosowania w nowotworach płuc, wykazujących ekspresję polipeptydów TTK, URLC10 lub KOC1 |
| CN100348614C (zh) | 2005-06-03 | 2007-11-14 | 北京大学 | 一种肝癌－睾丸特异性抗原蛋白质和抗原肽 |
| US20070099209A1 (en) * | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| EP2295570A1 (en) | 2005-07-27 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing small cell lung cancer |
| US8030443B2 (en) | 2005-08-09 | 2011-10-04 | Kurume University | Squamous cell carcinoma antigen-derived peptide binding to HLA-A24 molecule |
| WO2008102906A1 (en) * | 2007-02-20 | 2008-08-28 | Oncotherapy Science, Inc. | Hspc-hrpc transition genes |
| TWI615403B (zh) * | 2007-02-21 | 2018-02-21 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| EP1983003A3 (en) | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
-
2009
- 2009-10-15 EP EP09821762.3A patent/EP2362906B1/en active Active
- 2009-10-15 UA UAA201106195A patent/UA102274C2/ru unknown
- 2009-10-15 AU AU2009305847A patent/AU2009305847B2/en not_active Ceased
- 2009-10-15 BR BRPI0919766-4A patent/BRPI0919766B1/pt not_active IP Right Cessation
- 2009-10-15 CN CN200980151824.6A patent/CN102264897B/zh not_active Expired - Fee Related
- 2009-10-15 KR KR1020117011590A patent/KR101705150B1/ko not_active Expired - Fee Related
- 2009-10-15 RU RU2011120447/10A patent/RU2532105C2/ru active
- 2009-10-15 CA CA2741399A patent/CA2741399C/en active Active
- 2009-10-15 ES ES09821762.3T patent/ES2541325T3/es active Active
- 2009-10-15 WO PCT/JP2009/005382 patent/WO2010047062A1/en not_active Ceased
- 2009-10-15 MX MX2011004176A patent/MX2011004176A/es active IP Right Grant
- 2009-10-15 NZ NZ592461A patent/NZ592461A/xx not_active IP Right Cessation
- 2009-10-15 JP JP2011517539A patent/JP5663790B2/ja active Active
- 2009-10-15 CN CN201410198295.8A patent/CN104086625B/zh not_active Expired - Fee Related
- 2009-10-15 SG SG2013077631A patent/SG195571A1/en unknown
- 2009-10-15 US US13/125,548 patent/US8883966B2/en active Active
- 2009-10-21 TW TW098135570A patent/TWI455720B/zh not_active IP Right Cessation
- 2009-10-23 AR ARP090104100A patent/AR073967A1/es unknown
-
2011
- 2011-03-31 IL IL212046A patent/IL212046A/en active IP Right Grant
- 2011-04-26 CO CO11050897A patent/CO6362049A2/es active IP Right Grant
- 2011-05-19 ZA ZA2011/03667A patent/ZA201103667B/en unknown
-
2014
- 2014-09-29 US US14/500,877 patent/US9132176B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012500001A5 (enExample) | ||
| JP2010523471A5 (enExample) | ||
| CN109963585B (zh) | 包括细胞穿透肽、多表位和tlr肽激动剂的用于治疗癌症的融合物 | |
| JP2011524737A5 (enExample) | ||
| JP2010506826A5 (enExample) | ||
| ES2402184T3 (es) | Análogos de péptidos de unión a HLA sintéticos y sus usos | |
| JP2010519176A5 (enExample) | ||
| JP2013511958A5 (enExample) | ||
| JP2012517799A5 (enExample) | ||
| JP2010500399A5 (enExample) | ||
| RU2011110504A (ru) | Эпитопные пептиды inhbb и вакцины, содержащие данные пептиды | |
| JP2012500184A5 (enExample) | ||
| HRP20141233T1 (hr) | PEPTIDNA CJEPIVA DOBIVENA IZ EphA4 | |
| JP6786074B2 (ja) | エキソソーム標的ｄｎａワクチン | |
| RU2009141595A (ru) | Пептиды тем8 и содержащие их вакцины | |
| RU2012127358A (ru) | Олигопептиды imp-3 и содержащие их вакцины | |
| JP2011529683A5 (enExample) | ||
| JP2008530975A5 (enExample) | ||
| JP2013523084A5 (enExample) | ||
| RU2011110376A (ru) | Эпитопные пептиды hig2 и urlc10 и содержание их вакцины | |
| JP2012520659A5 (enExample) | ||
| JP2020528449A5 (enExample) | ||
| JP2013517764A5 (enExample) | ||
| JP2010514669A5 (enExample) | ||
| JP2014533095A5 (enExample) |